Original Publication Date: 27 March, 2014
Publication / Source: Pharmacogenomics
Authors: Melissa J LaBonte & Heinz-Josef Lenz
The last 20 years has witnessed a significant increase in our knowledge and understanding of the complex pathways and molecular signals that are deregulated in colorectal cancer (CRC). This remarkable progress has been made possible through numerous technological advances and extensive collaborative efforts within the pharmaceutical, clinical and research communities and has led to the identification of promising new drug targets and the development of new drugs.